Allograft vasculopathy: the Achilles' heel of heart transplantation
S Chih, AY Chong, LM Mielniczuk, DL Bhatt… - Journal of the American …, 2016 - jacc.org
Cardiac allograft vasculopathy (CAV) remains the Achilles' heel of long-term survival after
heart transplantation. Almost one-third of patients develop CAV by 5 years post-transplant …
heart transplantation. Almost one-third of patients develop CAV by 5 years post-transplant …
Cardiac allograft vasculopathy: current review and future research directions
JS Pober, S Chih, J Kobashigawa… - Cardiovascular …, 2021 - academic.oup.com
Cardiac allograft vasculopathy (CAV) is a pathologic immune-mediated remodelling of the
vasculature in transplanted hearts and, by impairing perfusion, is the major cause of late …
vasculature in transplanted hearts and, by impairing perfusion, is the major cause of late …
The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients
MR Costanzo, A Dipchand, R Starling… - The Journal of heart and …, 2010 - Elsevier
CHAIR: Costanzo MR: Midwest Heart Foundation, Lombard Illinois, USA TASK FORCE 1:
Dipchand A: Hospital for Sick Children, Toronto Ontario, Canada; Starling R: Cleveland …
Dipchand A: Hospital for Sick Children, Toronto Ontario, Canada; Starling R: Cleveland …
3ª diretriz brasileira de transplante cardíaco
F Bacal, FG Marcondes-Braga, LEP Rohde… - Arquivos brasileiros de …, 2018 - SciELO Brasil
Prezados colegas, Grandes avanços no diagnóstico, monitorização e tratamento da
Insuficiência Cardíaca (IC) foram observados nos últimos anos, com impactos reais na …
Insuficiência Cardíaca (IC) foram observados nos últimos anos, com impactos reais na …
Cardiac allograft vasculopathy: recent developments
D Schmauss, M Weis - Circulation, 2008 - Am Heart Assoc
Cardiac allograft vasculopathy (CAV) continues to limit the long-term success of cardiac
transplantation. Recent insights have underscored the fact that innate and adaptive immune …
transplantation. Recent insights have underscored the fact that innate and adaptive immune …
II Diretriz brasileira de transplante cardíaco
O transplante cardíaco persiste sendo o tratamento de escolha para a insuficiência cardíaca
refratária, apesar da grande melhora na expectativa de vida com o tratamento clínico …
refratária, apesar da grande melhora na expectativa de vida com o tratamento clínico …
Cardiac allograft vasculopathy: current knowledge and future direction
M Colvin‐Adams, A Agnihotri - Clinical transplantation, 2011 - Wiley Online Library
Colvin‐Adams M, Agnihotri A. Cardiac allograft vasculopathy: current knowledge and future
direction. Clin Transplant 2011: 25: 175–184.© 2011 John Wiley & Sons A/S. Abstract …
direction. Clin Transplant 2011: 25: 175–184.© 2011 John Wiley & Sons A/S. Abstract …
Cardiac allograft vasculopathy: the enduring enemy of cardiac transplantation
AP Nikolova, JA Kobashigawa - Transplantation, 2019 - journals.lww.com
Cardiac allograft vasculopathy remains a major limiting factor in the long-term survival of the
heart transplant recipient. Our understanding of its pathogenesis is continuously evolving as …
heart transplant recipient. Our understanding of its pathogenesis is continuously evolving as …
Cardiac allograft vasculopathy: insights on pathogenesis and therapy
F Lee, V Nair, S Chih - Clinical transplantation, 2020 - Wiley Online Library
Cardiac allograft vasculopathy (CAV) is a unique accelerated form of coronary vascular
disease affecting heart transplant recipients. This complication is a significant contributor to …
disease affecting heart transplant recipients. This complication is a significant contributor to …
Angiotensin-converting enzyme inhibition early after heart transplantation
WF Fearon, K Okada, JA Kobashigawa… - Journal of the American …, 2017 - jacc.org
Background: Cardiac allograft vasculopathy (CAV) remains a leading cause of mortality after
heart transplantation (HT). Angiotensin-converting enzyme inhibitors (ACEIs) may retard the …
heart transplantation (HT). Angiotensin-converting enzyme inhibitors (ACEIs) may retard the …